Theravance Biopharma
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
901 Gateway Blvd, South San Francisco, C...Phone Number
(650) 808-6000Website
www.theravance.comRevenue
$104.3 MillionStock Symbol
TBPHIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
2
1
About Theravance Biopharma
Theravance Biopharma, Inc. (\Theravance Biopharma\") is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. The company was founded in 2013 and is headquartered in South San Francisco, California."Explore more
Theravance Biopharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Theravance Biopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Theravance Biopharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Theravance Biopharma
Earning: See what the market has to say on Theravance Biopharma recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Theravance Biopharma is spiking on competitors!
Product Launch: Get notified when Theravance Biopharma launches new products
Theravance Biopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Theravance Biopharma has new funding data
Check if Theravance Biopharma has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Theravance Biopharma as Masked Content
Find 3 more new buyers
Compare Similar Companies to Theravance Biopharma
Compare insights from companies similar to Theravance Biopharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Theravance Biopharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Theravance Biopharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Theravance Biopharma.
Theravance Biopharma financials insights
Gather financial insights about Theravance Biopharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Share Placement
$55M
2016
Multiple Rounds
$407.8M
2018
Debt
$250M
2020
Stock Offering
$148.5M
Debt
$400M
Theravance Biopharma Tech Stack
A closer look at the technologies used by Theravance Biopharma
See more technologies
Most Recent Scoops
Project
Theravance Biopharma has entered into a commercial arrangement with Viatris and Theravance Biopharma under which Zymeworks will receive a 35% participation in US net profits from YUPELRI, with Viatris responsible for community promotion and Theravance managing the hospital setting.
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Divestiture
Theravance Biopharma has completed the sale of its remaining royalty interest in Trilogy to GSK for $225 million. This transaction significantly strengthens Theravance Biopharma's balance sheet and represents the first major outcome from its strategic review committee's efforts to unlock shareholder value.
Divestitures, Business Finance, Corporate Strategy, Finance
Project
reported that the Cypress trial for AMPRELOX was designed in collaboration with FDA to confirm benefits observed in Study 170 in a larger population of patients with MSA. The trial uses a randomized withdrawal design and includes an enrichment strategy to identify patients showing clear symptom benefits during the open label phase.
Research & Development, Pharmaceuticals, Clinical Operations
Earnings
Earnings, Accounting, Sales, Financial Reporting, Finance
Theravance Biopharma News & Media
Shareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholders
MILWAUKEE, June 29, 2026 /PRNewswire/ -- Ademi LLP is investigating Theravance Biopharma (NASDAQ: TBPH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Zymeworks. Click here to learn how to join our investigation and obtain...THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
Theravance Biopharma shareholders to receive $17.00 per share in cash, representing an equity value of approximately $929 million Theravance Biopharma shareholders to receive a contingent value right (CVR) entitling them to 80% of net proceeds from any future license, divestiture or other...Zymeworks to Acquire Theravance Biopharma, Inc.
VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the “Company”), a biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced it has entered into a definitive agreement to acquire Theravance Biopharma, Inc. (NASDAQ: TBPH); a biopharmaceutical company focused on delivering Medicines that Make a Difference® in people’s lives. This proposed acquisitINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. (“Theravance” or the “Company”) (NASDAQ: TBPH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Theravance Biopharma
Sign Up For FreeTo access detailed company insights
Theravance Biopharma, Inc. (\Theravance Biopharma\") is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. The company was founded in 2013 and is headquartered in South San Francisco, California."... Read More
